Intimation to shareholders about deduction of tax at source (TDS) on Final Dividend for FY 2026-26, if approved by the members at the ensuing AGM
DIVIDEND
● No Immediate Change
LOW RISK
📅 Filed on BSE: 01 Aug 2026, 10:56 PM IST · BSE ID: 04169a5c-8677-4f90-8c6a-0fff60b8ba7d
View Original BSE Filing (PDF)
💡
In Simple Terms
The company is explaining how taxes will be taken out of the final dividend, if shareholders approve it.
🤖 AI Summary
- Jubilant Pharmova Limited details TDS procedures for FY26 final dividend.
- Dividend payment is contingent on shareholder approval at the AGM.
- Shareholders must submit necessary forms for tax deduction compliance.
- Communication sent to shareholders on August 1, 2026.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Recommended Final Dividend per equity share for FY 2025-26
` 5
🏢 How This Affects the Company
The announcement details the tax implications for dividend distribution but does not alter the recommended dividend amount or the company's financial position.
Requires administrative processing for TDS compliance and communication with shareholders regarding necessary documentation.
👥 What This Means For Shareholders
✅
Action Required
Shareholders should review the communication regarding TDS on the final dividend and submit necessary forms if required for their tax status.
👤
Who Is Affected
All shareholders who are eligible to receive the final dividend for FY 2025-26, subject to its approval.
🔍
Management Signal
Management is ensuring adherence to tax regulations and providing clear procedural information to shareholders regarding dividend distribution.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Outcome of the Annual General Meeting regarding dividend approval.
Record date announcement for dividend payment.
Actual dividend payment date.
LOW RISK
This filing is an administrative update on dividend tax, with no inherent company-specific risks.
💡 Investor Takeaway
Jubilant Pharmova communicated TDS procedures for its recommended final dividend for FY 2025-26, contingent on AGM approval. Shareholders need to submit relevant forms for tax compliance.
⚖️ Strengths & Concerns
✅ Positives
- Clear communication on dividend tax procedures provided to shareholders.
- Dividend subject to necessary approvals, maintaining corporate governance.
❓ Frequently Asked Questions
What is Jubilant Pharmova Limited communicating regarding its final dividend for FY 2025-26?
Jubilant Pharmova Limited is intimating shareholders about the deduction of tax at source (TDS) on the final dividend for FY 2025-26.
What is the recommended final dividend per share for FY 2025-26?
The Board of Directors has recommended a final dividend of ` 5 per equity share for the Financial Year ended March 31, 2026.
When will the final dividend for FY 2025-26 be paid?
The payment of the final dividend is subject to the approval of the shareholders at the ensuing Annual General Meeting.
What action do shareholders need to take regarding the dividend tax?
Shareholders need to follow the procedures outlined for submitting relevant forms and documents to comply with TDS regulations.
Questions based on this BSE filing only. For information purposes.